Company intelligence / Profile preview

Vizgen

Cambridge, Massachusetts, United Statesvizgen.com ↗

Ownership: Private
Development stage: Commercial

Overview

Vizgen’s spatial genomics platforms are commercially available and widely adopted in academic and pharmaceutical research. The company’s technologies enable high-resolution single-cell spatial transcriptomics and proteomics for basic discovery through translational medicine. No clinical trial results apply as the company does not develop therapeutics but provides enabling technology for life science R&D.[1][2]

Therapeutic areas: ImmunologyOtherOncologyNeurologyInfectious Diseases
Modalities: DeviceSoftwareAssay technologyMultiomics analysis tools
Industry: Molecular Diagnostics

Partnerships

Hamamatsu Photonics (spatial biology workflow integration)Certified service providers in spatial genomics research collaborations

Beyond the preview

Go deeper on Vizgen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vizgen.

Explore the full profile